朗生醫藥(00503.HK)完成配售4952萬股 淨籌5915萬港元
格隆匯4月20日丨朗生醫藥(00503.HK)宣佈,認購協議所有條件均已達成,於公吿日期,向承配人配發併發行4952萬股配售股份已根據認購協議條款及條件完成。
認購事項所得款項總額及淨額分別約為5942萬港元及5915萬港元。公司擬將認購事項全部所得款項淨額用作用於(i)潛在的未來併購或項目;及(ii)補充營運資金及一般企業用途,以支持公司策略。
緊接認購事項完成前,公司已發行3.77億股股份。認購事項完成後,4952萬股新股份(相當於公司於公吿日期經配發併發行認購股份擴大的已發行股本約11.60%)已按認購價每股認購股份1.20港元以繳足股款的方式正式配發併發行予承配人。因此,緊隨認購事項完成後,已發行4.27億股股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.